But little research is done on male treatments, expert says
by DrewS on Tue Dec 13, 2011 06:37 AM
TBL-12 is used as an alternative or complementary cancer treatment due to its healing qualities. The product contains 100% natural ingredients that have no known side effects, interactions with medications or toxins. TBL-12 contains powerful anti-inflammatory, marine invertebrate. TBL-12 is a powerful, clinically tested immune modulator. Whether it's weakened or overactive, using TBL-12 allows the immune system to function properly. A proprietary processing procedure gives TBL-12 its unique healing qualities.TBL-12 is currently involved in two clinical trials assessing the value in using the product to treat Multiple Myeloma. There are more studies being planned to target other types of cancers and immune system related diseases. http://clinicaltrials.gov/ct2/show/NCT01096810 http://clinicaltrials.gov/ct2/show/NCT01302366 Research Paper:A recent abstract published in Blood Journal which have shown some fantastic results when taking TBL-12 with Velcade. The details of the abstract are:http://abstracts.hematologylibrary.org/cgi/content/abstract/ http://abstracts.hematologylibrary.org/cgi/content/abstract/ They currently have distribution setup in Australia and USA.
view their site for more information on the product:www.tbl-12.com
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.